Carmell Therapeutics Stock Performance
| CTCX Stock | 0.28 0.02 7.69% |
The firm shows a Beta (market volatility) of 6.75, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Carmell Therapeutics will likely underperform. At this point, Carmell Therapeutics has a negative expected return of -0.15%. Please make sure to confirm Carmell Therapeutics' total risk alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Carmell Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Carmell Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's fundamental indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
1 | Acquisition by Spenlehauer Gilles of 1009 shares of Carmell Therapeutics at 0.51 subject to Rule 16b-3 | 09/06/2024 |
2 | Acquisition by Bryan Cassaday of 475 shares of Carmell Therapeutics at 0.46 subject to Rule 16b-3 | 09/10/2024 |
3 | Acquisition by Upton Richard A of 5000 shares of Carmell Therapeutics at 0.4672 subject to Rule 16b-3 | 09/13/2024 |
4 | Meteora Capital, LLC Reduces Stake in Carmell Corp | 11/15/2024 |
| Begin Period Cash Flow | 128.1 K | |
| Free Cash Flow | -8.4 M |
Carmell |
Carmell Therapeutics Relative Risk vs. Return Landscape
If you would invest 50.00 in Carmell Therapeutics on August 31, 2024 and sell it today you would lose (22.00) from holding Carmell Therapeutics or give up 44.0% of portfolio value over 90 days. Carmell Therapeutics is currently does not generate positive expected returns and assumes 13.7633% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Carmell, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Carmell Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Carmell Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Carmell Therapeutics, and traders can use it to determine the average amount a Carmell Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0107
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CTCX |
Estimated Market Risk
| 13.76 actual daily | 96 96% of assets are less volatile |
Expected Return
| -0.15 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Carmell Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Carmell Therapeutics by adding Carmell Therapeutics to a well-diversified portfolio.
Carmell Therapeutics Fundamentals Growth
Carmell Stock prices reflect investors' perceptions of the future prospects and financial health of Carmell Therapeutics, and Carmell Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Carmell Stock performance.
| Return On Equity | -1.76 | ||||
| Return On Asset | -0.85 | ||||
| Operating Margin | (96.71) % | ||||
| Current Valuation | 5.41 M | ||||
| Shares Outstanding | 20.91 M | ||||
| Price To Book | 1.91 X | ||||
| Price To Sales | 468.34 X | ||||
| EBITDA | (15.19 M) | ||||
| Net Income | (15.45 M) | ||||
| Total Debt | 2.14 M | ||||
| Book Value Per Share | 1.07 X | ||||
| Cash Flow From Operations | (8.35 M) | ||||
| Earnings Per Share | 0.48 X | ||||
| Market Capitalization | 5.77 M | ||||
| Total Asset | 63.95 M | ||||
| Retained Earnings | (58.5 M) | ||||
| Working Capital | 24.4 M | ||||
About Carmell Therapeutics Performance
Evaluating Carmell Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Carmell Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Carmell Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.24) | (0.25) | |
| Return On Capital Employed | (0.21) | (0.19) | |
| Return On Assets | (0.24) | (0.25) | |
| Return On Equity | (0.62) | (0.59) |
Things to note about Carmell Therapeutics performance evaluation
Checking the ongoing alerts about Carmell Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Carmell Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Carmell Therapeutics generated a negative expected return over the last 90 days | |
| Carmell Therapeutics has high historical volatility and very poor performance | |
| Carmell Therapeutics has some characteristics of a very speculative penny stock | |
| Carmell Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (15.45 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Carmell Therapeutics generates negative cash flow from operations | |
| Carmell Therapeutics has a frail financial position based on the latest SEC disclosures | |
| About 34.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: Meteora Capital, LLC Reduces Stake in Carmell Corp |
- Analyzing Carmell Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Carmell Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Carmell Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Carmell Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Carmell Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Carmell Therapeutics' stock. These opinions can provide insight into Carmell Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Carmell Stock Analysis
When running Carmell Therapeutics' price analysis, check to measure Carmell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Carmell Therapeutics is operating at the current time. Most of Carmell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Carmell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Carmell Therapeutics' price. Additionally, you may evaluate how the addition of Carmell Therapeutics to your portfolios can decrease your overall portfolio volatility.